BACKGROUND: Endothelial progenitor cells (EPC) are a subpopulation of bone-marrow mononuclear cells that are capable of generating new blood vessels in areas of ischaemia or infarction. This review examines the regenerative potential of EPC to ameliorate peripheral ischaemia. METHODS: An online search was done using OVID Medline Search, PubMed, and Cochrane Review Database, for all reviews and original articles in English concerning progenitor or bone-marrow mononuclear cells. RESULTS AND CONCLUSION: There are many controversies in EPC research, especially in the areas of identification, characterization, and therapeutic use. Both animal and human studies have shown benefits from using EPC to combat peripheral arterial and cerebrovascular disease. To bring EPC into wider clinical use, larger controlled clinical trials and better methods of augmenting EPC function and lifespan are required. Until then EPC should be used under robust trial conditions with ethical approval.
BACKGROUND: Endothelial progenitor cells (EPC) are a subpopulation of bone-marrow mononuclear cells that are capable of generating new blood vessels in areas of ischaemia or infarction. This review examines the regenerative potential of EPC to ameliorate peripheral ischaemia. METHODS: An online search was done using OVID Medline Search, PubMed, and Cochrane Review Database, for all reviews and original articles in English concerning progenitor or bone-marrow mononuclear cells. RESULTS AND CONCLUSION: There are many controversies in EPC research, especially in the areas of identification, characterization, and therapeutic use. Both animal and human studies have shown benefits from using EPC to combat peripheral arterial and cerebrovascular disease. To bring EPC into wider clinical use, larger controlled clinical trials and better methods of augmenting EPC function and lifespan are required. Until then EPC should be used under robust trial conditions with ethical approval.
Authors: Akm Khyrul Wara; ShiYin Foo; Kevin Croce; Xinghui Sun; Basak Icli; Yevgenia Tesmenitsky; Fehim Esen; Jung-Soo Lee; Malayannan Subramaniam; Thomas C Spelsberg; Eli I Lev; Dorit Leshem-Lev; Reena L Pande; Mark A Creager; Anthony Rosenzweig; Mark W Feinberg Journal: Blood Date: 2011-08-09 Impact factor: 22.113
Authors: Kathryn Domanchuk; Luigi Ferrucci; Jack M Guralnik; Michael H Criqui; Lu Tian; Kiang Liu; Douglas Losordo; James Stein; David Green; Melina Kibbe; Lihui Zhao; Brian Annex; Harris Perlman; Donald Lloyd-Jones; William Pearce; Doris Taylor; Mary M McDermott Journal: Contemp Clin Trials Date: 2013-09-27 Impact factor: 2.226
Authors: Nina A Mikirova; James A Jackson; Ron Hunninghake; Julian Kenyon; Kyle W H Chan; Cathy A Swindlehurst; Boris Minev; Amit N Patel; Michael P Murphy; Leonard Smith; Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan Journal: J Transl Med Date: 2009-12-15 Impact factor: 5.531